JANE-2 will collaborate and develop synergies with ongoing EU Joint Actions, projects and initiatives being in compliance with Europe’s Beating Cancer Plan:
Joint Action EUnetCCC
JANE-2 will develop substantial synergies with the new Joint Action EUnetCCC “European Network on Comprehensive Cancer Centres”, officially in November 2024. The JA EUnetCCC has a duration of 4 years and builds on the results of the JA CraNE (October 2022-September 2024). The primary objective of the JA EUnetCCC is to create a cohesive and integrated consortium of CCCs across Europe to ensure that all patients, regardless of their location, have access to high-quality care. This network will also serve as a platform for collaboration, allowing Comprehensive Cancer Centres to share best practices, resources, and knowledge.
European Reference Networks (ERNs)
The European Reference Networks (ERNs) are cross-border networks that bring together European hospital centres of expertise and reference to tackle rare, low prevalence and complex diseases and conditions requiring highly specialised healthcare. ERNs enable specialists in Europe to discuss cases of patients affected by rare, low-prevalence and complex diseases, providing advice on the most appropriate diagnosis and the best treatment available.
JANE-2 will mostly interact with:
- EURACAN
EURACAN is a consortium of 102 European expert centres, European Patients Advocates (ePAGs) and relevant stakeholders whose goal is to improve access to care and clinical excellence for patients with Rare Adult Solid Cancers (RASCs) across the European Union and Ukraine. - GENTURIS
GENTURIS is a European Reference Network (ERN) for all patients with one of the rare genetic tumour risk syndromes (genturis). Genturis patients are at very high hereditary risk of developing common cancers, which are often located in multiple organ systems. In case they are diagnosed with cancer they may need different treatment and follow-up as compared to non-hereditary cancers. GENTURIS’ vision is to enable patients with genturis syndromes to receive appropriate diagnosis and treatment and for the healthcare professionals to enhance knowledge generation, get appropriate training and contribute in the research activities that are currently ongoing or will be available in the future. - PaedCan
Paediatric cancer comes in multiple subtypes and represents both a life-threatening disease and a major public health issue. With 35,000 children and adolescents newly diagnosed with cancer across Europe and 6,000 young patients dying each year, it remains the leading cause of death from disease for children older than 1 year of age. Significant inequalities in survival rates remain a challenge in Europe, with worse outcomes in Eastern Europe. The main goals of PaedCan are to reduce inequalities across Member States by enabling access to up-to-date diagnostics and treatments by facilitating the exchange of knowledge and expertise, establish Virtual Tumour Boards and provide cross-border healthcare to unite specialists across Europe and thus tackle complex or rare cancer conditions that require highly specialised interventions and a concentration of knowledge and resources.
eCAN
The eCAN Joint Action, strengthening eHealth for Cancer Patients, aims to provide a framework of recommendations for the integration of telemedicine and remote monitoring in health care systems.
